Clinical trials: MACE
Coronary Artery Calcification, Cardiovascular Risk
Artificial Intelligence - Based Opportunistic Coronary Artery Calcium Scoring on Routine Chest-CT Scan
This retrospective, non-interventional study externally validates a pre-trained open-weight deep-learning algorithm (Swin-UNETR) for the opportunistic quantification of coronary artery calcium (CAC) on non-gated routine chest CT…
- Conditions
- Coronary Artery Calcification, Cardiovascular Risk, Coronary Artery Disease, End-Stage Renal Disease Requiring Haemodialysis
- Trial name
- NCT07808593
- Volunteers
- 1,950 people
- Sponsor
- University of Cologne
Prostate Cancer
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enrollment in this study was discontinued by the Sponsor on 01 Dec 2023.
- Trial name
- NCT05605964
- Testing
- Relugolix, Leuprolide Acetate
- Where
- 108 sites in United States
- Volunteers
- 387 people
- Sponsor
- Sumitomo Pharma America, Inc.
Myocardial Injury After Non-cardiac Surgery, Urologic Cancer
Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients
This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for myocardial injury after non-cardiac surgery (MINS)…
- Conditions
- Myocardial Injury After Non-cardiac Surgery, Urologic Cancer, Major Adverse Cardiovascular Events (MACE)
- Trial name
- URO-MINS (NCT07634666)
- Testing
- No intervention assigned
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Korea University Anam Hospital
Obesity
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
- Trial name
- INFORMUS (NCT06098079)
- Testing
- Naltrexone-Bupropion (NB) Combination
- Where
- 140 sites in United States
- Volunteers
- 8,600 people
- Sponsor
- Currax Pharmaceuticals
Metabolic Syndrome
Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial…
- Trial name
- NCT02069717
- Testing
- Not applicable-observational study
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Fragmented QRS, Primary PCI
The Prognostic Significance of a Fragmented QRS Complex After Primary Percutaneous Coronary Intervention
To investigate the prognostic significance of a fragmented QRS (fQRS) complex in a patient who had undergone primary percutaneous coronary intervention (PCI).
- Conditions
- Fragmented QRS, Primary PCI, MACE
- Trial name
- NCT01136837
- Testing
- primary pcı
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people
- Sponsor
- Bursa Postgraduate Hospital
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE ONYX China Single Arm Study
It is a single arm clinical evaluation of safety and efficacy of the Medtronic Resolute Onyx™ zotarolimus-eluting coronary stent system in subjects who are eligible for percutaneous transluminal coronary angioplasty (PTCA) in de…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT03471845
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Medtronic Vascular
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE ONYX China RCT Study
It is a randomized controlled trial to evaluate the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in comparison with the Medtronic Resolute Integrity™ Zotarolimus-Eluting coronary…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT03466151
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
- Where
- 2 sites in China
- Volunteers
- 550 people
- Sponsor
- Medtronic Vascular
Hypogonadism, Cardiovascular Diseases
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
This is a double-blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
- Trial name
- TRAVERSE (NCT03518034)
- Testing
- AndroGel®
- Where
- 384 sites in United States, Puerto Rico
- Volunteers
- 5,246 people
- Sponsor
- AbbVie
Coronary Artery Disease
Coronary Atherosclerosis Disease Early Identification and Risk Stratification by Noninvasive Imaging
The investigator prospectively enroll 30,000 outpatients who were suspected of coronary artery disease (CAD) and underwent cardiac computed tomography angiography (CTA).
- Trial name
- Creation (NCT03518437)
- Where
- China
- Volunteers
- 30,000 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Model of Care for Hospitalized Older Adults
Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit
The purpose of this study is to determine if a new model of care, the Mobile Acute Care of the Elderly Unit is beneficial in improving patient outcomes for elderly patients admitted to the hospital.
- Trial name
- NCT00927160
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Asymptomatic, High Risk
Imaging vs. no Testing in Asymptomatic High-risk Diabetic Patients
The aim of our study was to evaluate 1- and 3-year outcome of alternative imaging strategies in asymptomatic high-risk diabetic patients: functional stress echocardiography combined with coronary flow reserve (CFR) and strain…
- Conditions
- Asymptomatic, High Risk, Diabetes
- Trial name
- FIND (NCT04388280)
- Testing
- Echocardiography, CT angiography
- Where
- Serbia
- Volunteers
- 400 people
- Sponsor
- Clinical Centre of Serbia
Peripheral Artery Disease
Cardiovascular Biomarkers in Peripheral Artery Disease.
Despite the best medical management, many patients with peripheral artery disease (PAD) who undergo lower extremity endovascular revascularization experience adverse cardiovascular outcomes and postoperative complications that…
- Trial name
- NCT05757258
- Where
- Italy
- Volunteers
- 207 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mild Autonomous Cortisol Excess
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and…
- Trial name
- NCT05038878
- Testing
- Elagolix
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease
SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent
Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability.
- Trial name
- NCT02150876
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Freiburg
Chronic Total Occlusion of Coronary Artery
A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter
This is a prospective, non-randomized, first-in-man investigational study, to assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional…
- Trial name
- NCT01978860
- Testing
- NovaCross, CTO
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Chanan Schneider
Hypercholesterolemia, Type 2 Diabetes
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments
The study is being conducted to compare the effect of standard treatment (target LDL-C level: <120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: <70 mg/dL) in the prevention of major adverse…
- Conditions
- Hypercholesterolemia, Type 2 Diabetes, Hypertension
- Trial name
- POSITIVE (NCT01173939)
- Testing
- Pravastatin, Rosuvastatin
- Where
- 317 sites in Japan
- Volunteers
- 10,000 people
- Sponsor
- Positive Trial Group
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Adrenal Incidentaloma
Natural History of NFAI: 10 Year Follow-up Results
The data on long term natural history of benign nonfunctioning adrenal tumors (NFATs) are lacking. The aim is to identify clinical characteristics associated with tumor growth and progression to mild autonomous cortisol excess…
- Trial name
- NCT04616703
- Testing
- CT imaging
- Where
- Slovenia
- Volunteers
- 65 people
- Sponsor
- University Medical Centre Ljubljana
Sedentary Behaviour, Stroke
Effectiveness of the RISE Intervention
Study aim: Primarily, to investigate the effectiveness of the RISE blended behaviour change intervention in people with a first stroke to prevent major adverse cardiovascular events (i.e., recurrent stroke or TIA, acute coronary…
- Trial name
- RISE (NCT06124248)
- Testing
- RISE intervention
- Where
- 21 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- UMC Utrecht